Related Experiment Video
Updated: Jul 5, 2026
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
Clinical value of PTEN in patients with superficial bladder cancer
Kyung Seok Han1, In Gab Jeong, Jae Young Joung
1Urologic Oncology Clinic, National Cancer Center, Goyang, Korea.
Introduction:
Frequent mutations or deletions of PTEN (phosphatase and tensin homolog deleted on chromosome 10) are reported in bladder cancer, while there are few studies which evaluated PTEN as a clinical prognostic parameter of superficial bladder cancer. We prospectively evaluated PTEN expression in patients with superficial bladder cancer by immunohistochemical staining and defined the value of PTEN mutations in predicting tumor behavior of superficial bladder cancer.
Materials And Methods:
A total of 190 patients were enrolled in this study. All of the patients underwent transurethral resection of bladder tumor and had superficial tumors. All pathologic materials used in this study were obtained from transurethral resection of bladder tumor. Immunohistochemical stainings were performed. The immunohistochemical staining intensity was judged to be either normal or reduced compared with the PTEN protein expression of positive and negative controls. Disappearance of more than 50% stained cytoplasmic granules was defined as reduced PTEN expression.
Results:
The alteration of PTEN expression was significantly different according to tumor stage and grade (p = 0.03, p = 0.048), especially high in carcinoma in situ. However, PTEN expression was not significantly correlated with disease recurrence, progression and recurrence- or progression-free survival.
Conclusions:
Reduced PTEN expression relates to aggressiveness of bladder tumors but seems not to have enough specificity for clinical use in the management of superficial bladder cancer.
